Compound Explorer
All 696 entries in our encyclopedia in one table, filterable by evidence grade, FDA status, molecule class, half-life, route and WADA status. Every cell comes from the same dataset the entry pages are built from; open an entry for its sources. Grades follow our methodology, and the WADA column reads the 2026 Prohibited List as recorded in each entry. Nothing here is a recommendation, and nothing is sold or linked.
696 of 696 entries
| Compound | Class | Category | FDA status | Evidence | Half-life | Route | WADA 2026 |
|---|---|---|---|---|---|---|---|
| 3PRGD2 Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| 5-Amino-1MQ | Small molecule, not a peptide | Metabolic | Research Chemical | Low | Undetermined in humans | Oral | Prohibited (S0 catch-all) |
| Abaloparatide Full entry | Peptide | Healing & Recovery | FDA Approved | High | ≈ 1 hour | Injection | Not on the 2026 List |
| Abarelix Full entry | Peptide | Sexual Health | Withdrawn | High | ≈ 10 days | Injection | Unsettled (S0 may apply) |
| ACE-031 | Protein, not a peptide | Research | Discontinued | Medium | ≈ 12.5 days | Injection | Prohibited at all times (S4.3) |
| Acetyl Decapeptide-3 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Dipeptide-1 Cetyl Ester | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Dipeptide-3 Aminohexanoate | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Heptapeptide-4 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Hexapeptide-1 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Hexapeptide-30 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Hexapeptide-37 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Hexapeptide-38 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Hexapeptide-49 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Hexapeptide-51 Amide | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Octapeptide-3 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Pentapeptide-1 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl SH-Heptapeptide-1 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tetrapeptide-11 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tetrapeptide-15 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tetrapeptide-2 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tetrapeptide-22 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tetrapeptide-3 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tetrapeptide-5 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tetrapeptide-9 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Acetyl Tripeptide-1 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Aclerastide | Peptide | Healing & Recovery | Discontinued | Low | Longer-acting than angiotensin-(1-7); applied topically once daily | Topical or eye | Not on the 2026 List |
| Adamax | Peptide | Cognitive | Research Chemical | Low | Undetermined in humans | Injection, Nasal | Prohibited (S0 catch-all) |
| Adipotide | Peptide | Research | Preclinical | Low | Preclinical; not characterized in humans | Injection | Prohibited (S0 catch-all) |
| Adrenomedullin Full entry | Peptide | Cardiovascular | Research Chemical | Medium | About 22 minutes (circulating, in people) | Injection | Prohibited (S0 catch-all) |
| Adrenomedullin 2 Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Adrenorphin (Metorphamide) Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans; a small endogenous peptide subject to rapid peptidase cleavage | Not stated | Not on the 2026 List |
| Adropin Full entry | Peptide | Metabolic | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Afamelanotide Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 15 hours | Injection | Not on the 2026 List |
| Agouti-Related Peptide (AgRP) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans; an endogenous central signalling peptide | Not stated | Not on the 2026 List |
| AHK-Cu | Peptide | Cosmetic | Research Chemical | Low | Undetermined | Topical or eye | Prohibited (S0 catch-all) |
| Alamandine Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not established for humans as a drug; a short endogenous RAS peptide | Not stated | Not on the 2026 List |
| Albiglutide Full entry | Protein, not a peptide | Metabolic | Discontinued | High | ≈ 5 days | Injection | Prohibited (S0 catch-all) |
| Albuvirtide Full entry | Peptide | Immune | Not FDA Approved | High | Not stated | Not stated | Not on the 2026 List |
| Alexamorelin | Peptide | Growth Hormone | Research Chemical | Low | Not measured in people | Injection | Prohibited at all times (S2.2.4) |
| AlF-NOTA-octreotide Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Alfatide II Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Alpha-MSH Full entry | Peptide | Immune | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Alprostadil Full entry | Small molecule, not a peptide | Sexual Health | FDA Approved | High | No figure on the label, which reports that about 80% is metabolised in one pass through the lungs | Injection | Not on the 2026 List |
| Amilomotide Full entry | Peptide conjugate | Cognitive | Not FDA Approved | Medium | Not applicable: a vaccine; trials measured antibody titres, not the drug | Injection | Prohibited (S0 catch-all) |
| Amycretin Full entry | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Suitable for weekly SC / daily oral | Injection, Oral | Prohibited (S0 catch-all) |
| Amylin Full entry | Peptide | Metabolic | Research Chemical | Low | Not reported for human amylin in the sources read | Not stated | Prohibited (S0 catch-all) |
| Anamorelin Full entry | Small molecule, not a peptide | Growth Hormone | Not FDA Approved | High | 6 to 7 hours (terminal) | Oral | Prohibited at all times (S2.2.4) |
| Angiotensin II Full entry | Peptide | Cardiovascular | FDA Approved | High | ≈ 1 minute | Injection | Not on the 2026 List |
| Angiotensin-(1-7) Full entry | Peptide | Cardiovascular | Research Chemical | Medium | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Anidulafungin Full entry | Peptide | Immune | FDA Approved | High | ≈ 43 hours | Not stated | Not on the 2026 List |
| ANP Full entry | Peptide | Cardiovascular | Not FDA Approved | High | Not reported in the sources read | Not stated | Unsettled (S0 may apply) |
| Anserine Full entry | Peptide | Longevity | Dietary Supplement | Medium | Short after oral intake; partly hydrolysed by carnosinase enzymes | Oral | Not on the 2026 List |
| AOD-9604 Full entry | Peptide | Metabolic | Research Chemical | Medium | Not published for people | Injection | Prohibited at all times (S2.2.3) |
| Apamin Full entry | Peptide | Cognitive | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Apelin Full entry | Peptide | Cardiovascular | Research Chemical | Medium | Not reported in the abstracts read | Not stated | Prohibited (S0 catch-all) |
| Apidaecin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a short linear peptide subject to proteolysis, analogs engineered for stability | Not stated | Not on the 2026 List |
| Apitegromab Full entry | Antibody, not a peptide | Pipeline & In-Development | FDA Approved | High | ≈ 31.2 days | Injection | Prohibited at all times (S4.3) |
| Apraglutide Full entry | Peptide | Pipeline & In-Development | In Development | High | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Aprotinin Full entry | Protein, not a peptide | Cardiovascular | Discontinued | High | ≈ 150 minutes | Injection | Unsettled (S0 may apply) |
| ARA-290 Full entry | Peptide | Healing & Recovery | In Clinical Trials | Medium | Short; no human value in the published abstracts | Injection | Prohibited at all times (S2.1.5) |
| Arenicin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a disulfide-stabilised beta-hairpin, more protease-resistant than linear AMPs | Not stated | Not on the 2026 List |
| Argireline Full entry | Peptide | Cosmetic | Research Chemical | Medium | Not reported in the sources read (topical use) | Topical or eye | Unsettled (S0 may apply) |
| Asprosin Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans; an endogenous circulating hormone | Not stated | Not on the 2026 List |
| Atosiban Full entry | Peptide | Sexual Health | Not FDA Approved | High | ≈ 1.7 hours | Injection | Not on the 2026 List |
| Augurin (ECRG4) Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans as a drug; an endogenous secreted peptide | Not stated | Not on the 2026 List |
| Aurein Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; short cationic/amphipathic peptides subject to proteolysis | Not stated | Not on the 2026 List |
| Avexitide | Peptide | Metabolic | In Clinical Trials | Medium | Not stated | Injection | Prohibited (S0 catch-all) |
| Avorelin | Peptide | Sexual Health | Discontinued | Low | Long-acting; a single subcutaneous depot suppressed testosterone for about 40 weeks | Injection | Prohibited (S0 catch-all) |
| Azagly-nafarelin | Peptide | Sexual Health | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited in males, at all times (S2.2.1) |
| AZD6234 | Peptide | Pipeline & In-Development | In Clinical Trials | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Azetirelin | Peptide | Cognitive | Discontinued | Low | Longer-acting than TRH; no human pharmacokinetic value published | Not stated | Prohibited (S0 catch-all) |
| B7-33 | Peptide | Cardiovascular | Preclinical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Bacitracin Full entry | Blend or mixture | Immune | FDA Approved | High | Not applicable to the topical product; systemic use was abandoned for kidney toxicity | Topical or eye | Not on the 2026 List |
| Balenine Full entry | Peptide | Research | Research Chemical | Medium | About 35 minutes in human plasma in vitro (2023) | Oral | Not on the 2026 List |
| Balixafortide | Peptide | Research | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Beinaglutide Full entry | Peptide | Metabolic | Not FDA Approved | Medium | Short; peak level 10 to 15 minutes after injection | Injection | Unsettled (S0 may apply) |
| Beta-Casomorphin-7 (BCM-7) Full entry | Peptide | Metabolic | Research Chemical | Low | Short; degraded by the ectoenzyme CD10 (neprilysin), which limits its duration | Not stated | Not on the 2026 List |
| Beta-Endorphin Full entry | Peptide | Cognitive | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Beta-lipotropin Full entry | Protein, not a peptide | Growth Hormone | Research Chemical | Low | ≈ 95 minutes | Not stated | Not on the 2026 List |
| Bimagrumab Full entry | Antibody, not a peptide | Pipeline & In-Development | In Clinical Trials | Medium | Fc-mediated; weeks | Injection | Prohibited at all times (S4.3) |
| Bioactive Food Peptides Full entry | Peptide | Research | Dietary Supplement | Medium | Variable — dipeptides and tripeptides absorbed intact via PepT1; larger peptides degraded | Oral | Not on the 2026 List |
| Biotinoyl Tripeptide-1 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Bivalirudin Full entry | Peptide | Cardiovascular | FDA Approved | High | ≈ 25 minutes | Injection | Not on the 2026 List |
| Bleomycin Full entry | Peptide | Research | FDA Approved | High | ≈ 2 hours | Injection | Not on the 2026 List |
| BNP | Peptide | Cardiovascular | Diagnostic Test Only | High | About 18 minutes for recombinant BNP (nesiritide) | Not stated | Not on the 2026 List |
| Bofanglutide Full entry | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | ≈ 7 days | Injection | Prohibited (S0 catch-all) |
| Bombesin Full entry | Peptide | Metabolic | Research Chemical | Medium | Short-acting; given by continuous infusion in human research studies | Injection | Not on the 2026 List |
| Botulinum Toxin Full entry | Protein, not a peptide | Cosmetic | FDA Approved | High | Not a blood half-life: it acts where it is injected, at nerve endings | Injection | Not on the 2026 List |
| BPC-157 Full entry | Peptide | Healing & Recovery | Research Chemical | Low | Short systemic half-life (minutes) but prolonged tissue effect | Injection, Oral | Prohibited at all times (S0) |
| Bradykinin Full entry | Peptide | Cardiovascular | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Brevinin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; cationic amphipathic peptides subject to proteolysis | Not stated | Not on the 2026 List |
| Brimapitide Full entry | Peptide | Research | Not FDA Approved | Medium | 0.36-0.65 hours (geometric means) after a 60-minute intravenous infusion in healthy men | Not stated | Prohibited (S0 catch-all) |
| BRN2 (POU3F2) Research Peptide | Peptide | Cognitive | Research Chemical | Low | Not characterized | Not stated | Prohibited (S0 catch-all) |
| Bronchogen | Peptide | Longevity | Research Chemical | Low | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| Buforin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a cationic peptide subject to proteolysis | Not stated | Not on the 2026 List |
| Bulevirtide Full entry | Peptide | Immune | FDA Approved | High | ≈ 3 hours | Injection | Not on the 2026 List |
| Buserelin Full entry | Peptide | Sexual Health | Not FDA Approved | High | Not reported in the sources read | Injection, Nasal | Prohibited in males, at all times (S2.2.1) |
| C-peptide Full entry | Peptide | Metabolic | Research Chemical | Medium | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Cagrilintide Full entry | Peptide | Metabolic | In Clinical Trials | Medium | 174-186 h (geometric means) after one dose of cagrilintide alone; 159-195 h when given weekly with semaglutide | Injection | Prohibited (S0 catch-all) |
| CagriSema Full entry | Blend or mixture | Pipeline & In-Development | In Development | High | Cagrilintide 159-195 h; semaglutide 145-165 h (given together weekly, phase 1b) | Injection | Prohibited (S0 catch-all) |
| Calcitonin Full entry | Peptide | Healing & Recovery | FDA Approved | High | ≈ 58 minutes | Injection, Nasal | Not on the 2026 List |
| Canvuparatide Full entry | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | 79-95 h (prodrug) and 184-213 h (active peptide) after four weekly doses | Injection | Prohibited (S0 catch-all) |
| Capreomycin Full entry | Peptide | Immune | Discontinued | Medium | Not stated | Not stated | Unsettled (S0 may apply) |
| Capromorelin Full entry | Small molecule, not a peptide | Growth Hormone | Veterinary Only | High | Not reported in people in the sources read | Not stated | Prohibited at all times (S2.2.4) |
| Caprooyl Tetrapeptide-3 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Carbetocin Full entry | Peptide | Sexual Health | Not FDA Approved | High | ≈ 41 minutes | Not stated | Not on the 2026 List |
| Cardiogen | Peptide | Longevity | Research Chemical | Low | Undetermined | Injection, Oral | Prohibited (S0 catch-all) |
| Carfilzomib Full entry | Peptide | Research | FDA Approved | High | ≈ 1 hour | Injection | Not on the 2026 List |
| Carnosine Full entry | Peptide | Longevity | Dietary Supplement | Medium | Rapidly degraded in blood by serum carnosinase | Oral | Not on the 2026 List |
| Carperitide Full entry | Peptide | Cardiovascular | Not FDA Approved | Medium | ≈ 3 minutes | Injection | Unsettled (S0 may apply) |
| CART peptide Full entry | Peptide | Metabolic | Research Chemical | Low | Not stated | Not stated | Not on the 2026 List |
| Cartalax | Peptide | Longevity | Research Chemical | Low | Undetermined | Oral | Prohibited (S0 catch-all) |
| Caspofungin Full entry | Peptide | Immune | FDA Approved | High | ≈ 10 hours | Injection | Not on the 2026 List |
| Catestatin Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not established for humans; an endogenous circulating peptide | Not stated | Not on the 2026 List |
| Cathelicidin | Protein, not a peptide | Immune | Research Chemical | Low | Not measured in people in the sources read | Not stated | Prohibited (S0 catch-all) |
| Cecropin Full entry | Peptide | Immune | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Cenderitide | Peptide | Cardiovascular | In Clinical Trials | Low | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Cerebrolysin Full entry | Blend or mixture | Cognitive | Not FDA Approved | High | Varies by component | Injection | Unsettled (S0 may apply) |
| Cerluten | Peptide | Longevity | Not FDA Approved | Low | Not characterized | Oral | Prohibited (S0 catch-all) |
| Certepetide Full entry | Peptide | Research | In Clinical Trials | Medium | ≈ 2 hours | Injection | Prohibited (S0 catch-all) |
| Ceruletide Full entry | Peptide | Metabolic | Discontinued | Low | Not stated | Not stated | Unsettled (S0 may apply) |
| Cetrorelix Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 20.6 hours | Injection | Not on the 2026 List |
| CGRP Full entry | Peptide | Cardiovascular | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Cholecystokinin Full entry | Peptide | Metabolic | Diagnostic Test Only | High | Not reported in the sources read | Not stated | Unsettled (S0 may apply) |
| Chonluten | Peptide | Longevity | Research Chemical | Low | Undetermined | Oral, Nasal | Prohibited (S0 catch-all) |
| Chromofungin Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not established for humans as a drug; a chromogranin-A-derived peptide | Not stated | Not on the 2026 List |
| Cilengitide Full entry | Peptide | Research | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| CJC-1293 | Peptide | Growth Hormone | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited at all times (S2.2.4) |
| CJC-1295 Full entry | Peptide | Growth Hormone | Research Chemical | Medium | 5.8–8.1 days (with DAC) | Injection | Prohibited at all times (S2.2.4) |
| Clavanin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; short peptide, chirality-inverted mimetics engineered for protease stability | Not stated | Not on the 2026 List |
| CNP Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Colistin Full entry | Peptide | Immune | FDA Approved | High | ≈ 2.5 hours | Injection | Not on the 2026 List |
| Colivelin (CLN) Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans; a short synthetic peptide studied by CNS and nasal delivery | Not stated | Not on the 2026 List |
| Collagen Peptides Full entry | Blend or mixture | Cosmetic | Dietary Supplement | Medium | Not established | Oral | Not on the 2026 List |
| Colostrinin Full entry | Peptide | Cognitive | Dietary Supplement | Low | Not reported in the sources read | Oral | Not on the 2026 List |
| Colulintide | Peptide | Pipeline & In-Development | Discontinued | Low | Not published | Injection | Prohibited (S0 catch-all) |
| Copeptin Full entry | Peptide | Cardiovascular | Research Chemical | Medium | About twice that of vasopressin (estimated initial half-life) | Not stated | Not on the 2026 List |
| Copper Cu 64 dotatate Full entry | Peptide conjugate | Research | FDA Approved | High | Not stated | Not stated | Not on the 2026 List |
| Corifollitropin alfa Full entry | Protein, not a peptide | Sexual Health | Not FDA Approved | High | ≈ 65 hours | Injection | Not on the 2026 List |
| Cortagen | Peptide | Longevity | Research Chemical | Low | Undetermined | Injection | Prohibited (S0 catch-all) |
| Cortexin Full entry | Blend or mixture | Cognitive | Not FDA Approved | Low | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| Corticorelin Full entry | Peptide | Growth Hormone | FDA Approved | High | ≈ 73 minutes | Injection | Prohibited at all times (S2.2.2) |
| Corticotropin Full entry | Peptide | Growth Hormone | FDA Approved | High | ≈ 15 minutes | Injection | Prohibited at all times (S2.2.2) |
| Corticotropin-like intermediate peptide (CLIP) Full entry | Peptide | Research | Research Chemical | Low | Not stated in the sources read | Not stated | Not on the 2026 List |
| Cortistatin Full entry | Peptide | Growth Hormone | Research Chemical | Low | Not stated | Injection | Prohibited (S0 catch-all) |
| Cotadutide Full entry | Peptide | Pipeline & In-Development | Discontinued | Medium | ≈ 11 hours | Injection | Prohibited (S0 catch-all) |
| CP04 | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Cyclic Glycine-Proline Full entry | Peptide | Research | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Cyclo(His-Pro) Full entry | Peptide | Research | Research Chemical | Low | Not measured in people; long in mouse blood, with no figure given | Injection | Prohibited (S0 catch-all) |
| Cyclosporine Full entry | Peptide | Immune | FDA Approved | High | ≈ 8.4 hours | Not stated | Not on the 2026 List |
| D-4F Full entry | Peptide | Cardiovascular | Research Chemical | Low | Short; peak 30 minutes to 2 hours after oral doses | Oral | Prohibited (S0 catch-all) |
| Dactinomycin Full entry | Peptide | Research | FDA Approved | High | ≈ 25 hours | Injection | Not on the 2026 List |
| Dalazatide | Peptide | Immune | Not FDA Approved | Medium | Not reported in people; slow absorption, days of exposure in monkeys | Injection | Prohibited (S0 catch-all) |
| Dalbavancin Full entry | Peptide | Immune | FDA Approved | High | ≈ 204 hours | Injection | Not on the 2026 List |
| Danegaptide Full entry | Peptide | Cardiovascular | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Danuglipron Full entry | Small molecule, not a peptide | Pipeline & In-Development | Discontinued | Medium | Not reported; tested twice daily, then once daily | Oral | Prohibited (S0 catch-all) |
| Dapiglutide | Peptide | Metabolic | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| DAPTA Full entry | Peptide | Immune | Not FDA Approved | Medium | 30-60 minutes (first phase) then 4-6 hours (second phase) after intravenous or intranasal dosing | Nasal | Prohibited (S0 catch-all) |
| Daptomycin Full entry | Peptide | Immune | FDA Approved | High | ≈ 8 hours | Injection | Not on the 2026 List |
| Dasiglucagon Full entry | Peptide | Metabolic | Discontinued | High | ≈ 30 minutes | Injection | Not on the 2026 List |
| Davalintide | Peptide | Metabolic | Discontinued | Low | Short in blood (~26 min in rats) but a much longer action from slow receptor release | Not stated | Not on the 2026 List |
| Davunetide Full entry | Peptide | Cognitive | In Clinical Trials | Medium | Not established in published human studies | Nasal | Prohibited (S0 catch-all) |
| Dazdotuftide Full entry | Peptide conjugate | Immune | In Clinical Trials | Medium | Not reported in the sources read | Topical or eye | Prohibited (S0 catch-all) |
| Decapeptide-12 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Degarelix Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 53 days | Injection | Not on the 2026 List |
| Deltorphin Full entry | Peptide | Cognitive | Research Chemical | Low | Longer-lived than ordinary peptides; the D-amino acid resists enzymatic breakdown | Not stated | Not on the 2026 List |
| Demoxytocin Full entry | Peptide | Sexual Health | Discontinued | Medium | Longer-acting than oxytocin; buccal effect peaks in about 1-2 hours | Oral | Not on the 2026 List |
| Depreotide Full entry | Peptide | Research | Discontinued | Medium | Not reported in the sources read | Injection | Not on the 2026 List |
| Dermcidin Full entry | Peptide | Immune | Research Chemical | Medium | Hours on skin surface | Not stated | Prohibited (S0 catch-all) |
| Dermorphin Full entry | Peptide | Research | Research Chemical | Low | Limited human PK | Not stated | Not on the 2026 List |
| Des-acyl Ghrelin (Unacylated Ghrelin) Full entry | Peptide | Metabolic | Research Chemical | Medium | Not established as an approved drug; an endogenous circulating peptide | Not stated | Not on the 2026 List |
| Desirudin Full entry | Protein, not a peptide | Cardiovascular | Discontinued | High | ≈ 2 hours | Injection | Unsettled (S0 may apply) |
| Deslorelin Full entry | Peptide | Sexual Health | Veterinary Only | Medium | Not reported in the sources read | Injection | Prohibited in males, at all times (S2.2.1) |
| Desmopressin Full entry | Peptide | Cardiovascular | FDA Approved | High | ≈ 2 hours | Injection, Oral, Nasal | Prohibited at all times (S5) |
| Detirelix Full entry | Peptide | Sexual Health | Discontinued | Medium | At least 41 h in men after a single subcutaneous dose (by immunoassay) | Injection | Prohibited (S0 catch-all) |
| Difelikefalin Full entry | Peptide | Healing & Recovery | FDA Approved | High | ≈ 27 hours | Injection | Not on the 2026 List |
| Dihexa Full entry | Peptidomimetic | Cognitive | Research Chemical | Low | Undetermined in humans | Oral | Prohibited (S0 catch-all) |
| Dipeptide-2 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Dirucotide | Peptide | Immune | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Disomotide Full entry | Peptide | Research | Not FDA Approved | Medium | Not reported: a depot vaccine, measured by the T cells it raises rather than by blood levels | Injection | Prohibited (S0 catch-all) |
| Dolcanatide | Peptide | Healing & Recovery | Not FDA Approved | Low | Not stated in the sources read | Oral | Prohibited (S0 catch-all) |
| DOTA-EB-TATE Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| DOTA-LM3 Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| DOTA-MGS5 | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| DOTAMTATE | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| DOTANOC Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Drosocin Full entry | Peptide | Immune | Research Chemical | Low | Short for the natural peptide; hydroxyproline-substituted analogs are several times more stable in serum | Not stated | Not on the 2026 List |
| DSIP Full entry | Peptide | Cognitive | Research Chemical | Medium | Not measured in people; about 2 to 4 minutes after IV injection in dogs, a monkey and rats | Injection | Prohibited (S0 catch-all) |
| Dulaglutide Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | ≈ 5 days | Injection | Not on the 2026 List |
| Dusquetide | Peptide | Immune | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Dynorphin Full entry | Peptide | Cognitive | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Ebiratide Full entry | Peptide | Cognitive | Discontinued | Low | Not measured in people | Injection | Prohibited (S0 catch-all) |
| Ecallantide Full entry | Protein, not a peptide | Immune | FDA Approved | High | ≈ 2 hours | Not stated | Not on the 2026 List |
| ECC5004 | Small molecule, not a peptide | Pipeline & In-Development | In Clinical Trials | Medium | Not reported | Oral | Prohibited (S0 catch-all) |
| Ecnoglutide Full entry | Peptide | Metabolic | Not FDA Approved | High | ≈ 131 hours | Injection | Unsettled (S0 may apply) |
| Edotreotide Full entry | Peptide conjugate | Research | FDA Approved | High | Not stated | Injection | Not on the 2026 List |
| Edratide Full entry | Peptide | Immune | Not FDA Approved | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Efinopegdutide | Peptide | Metabolic | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Efmedaglutide alfa | Protein, not a peptide | Pipeline & In-Development | In Clinical Trials | Low | About 110 to 185 hours | Injection | Prohibited (S0 catch-all) |
| Efocipegtrutide | Peptide conjugate | Pipeline & In-Development | In Clinical Trials | Low | About 72 to 191 hours in phase 1 (company abstracts) | Injection | Prohibited (S0 catch-all) |
| Efpeglenatide Full entry | Peptide conjugate | Pipeline & In-Development | In Clinical Trials | High | ≈ 158 hours | Injection | Prohibited (S0 catch-all) |
| Efruxifermin Full entry | Protein, not a peptide | Pipeline & In-Development | In Clinical Trials | Medium | 3 to 3.5 days (PMID 33205064) | Injection | Unsettled (S2.3 may apply) |
| Efsubaglutide alfa Full entry | Protein, not a peptide | Metabolic | Not FDA Approved | High | About 182–215 hours in type 2 diabetes (population model); mean 121 hours after single doses in healthy adults | Injection | Unsettled (S0 may apply) |
| Eftansomatropin alfa | Protein, not a peptide | Pipeline & In-Development | Not FDA Approved | Medium | Not stated in the sources read | Injection | Prohibited at all times (S2.2.3) |
| Elabela Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Elagolix Full entry | Small molecule, not a peptide | Sexual Health | FDA Approved | High | ≈ 6 hours | Oral | Not on the 2026 List |
| Elamipretide Full entry | Peptide | Longevity | FDA Approved | High | Dosed once daily by subcutaneous injection | Injection | Not on the 2026 List |
| Elcatonin Full entry | Peptide | Healing & Recovery | Not FDA Approved | Medium | Not reported in the sources read | Injection | Not on the 2026 List |
| Eloralintide Full entry | Peptide | Metabolic | In Clinical Trials | Medium | Supports once-weekly dosing | Injection | Prohibited (S0 catch-all) |
| Elpamotide Full entry | Peptide | Research | Not FDA Approved | Medium | Not reported: a depot vaccine in oil adjuvant, judged by the T cells it raises rather than by blood levels | Injection | Prohibited (S0 catch-all) |
| Elsiglutide | Peptide | Pipeline & In-Development | Discontinued | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| EM66 Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous granin peptide | Not stated | Not on the 2026 List |
| Emodepside Full entry | Peptide | Research | Veterinary Only | Medium | ≈ 500 hours | Oral | Prohibited (S0 catch-all) |
| Endoluten | Peptide | Longevity | Not FDA Approved | Low | Not reported | Oral | Prohibited (S0 catch-all) |
| Endomorphin-1 Full entry | Peptide | Cognitive | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Endomorphin-2 (EM-2) Full entry | Peptide | Cognitive | Research Chemical | Low | Very short; the native peptide is rapidly degraded by peptidases | Not stated | Not on the 2026 List |
| Endothelin-1 Full entry | Peptide | Cardiovascular | Research Chemical | Medium | About 1 to 2 minutes in plasma after infusion (initial phase); its constriction outlasts it | Not stated | Prohibited (S0 catch-all) |
| Eneboparatide Full entry | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Short; peak 5-20 minutes after injection | Injection | Prohibited (S0 catch-all) |
| Enfuvirtide Full entry | Peptide | Immune | Discontinued | High | ≈ 3.8 hours | Injection | Not on the 2026 List |
| Enicepatide | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Supports once-weekly dosing | Injection | Prohibited (S0 catch-all) |
| Enkephalin Full entry | Peptide | Cognitive | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Enlicitide Full entry | Peptide | Cardiovascular | FDA Approved | High | ≈ 14 hours | Oral | Not on the 2026 List |
| Enterostatin Full entry | Peptide | Metabolic | Research Chemical | Low | Not characterised in people | Oral | Prohibited (S0 catch-all) |
| Epinecidin-1 Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a short cationic peptide, variants engineered for stability | Not stated | Not on the 2026 List |
| Epithalamin Full entry | Blend or mixture | Longevity | Research Chemical | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Epithalon Full entry | Peptide | Longevity | Research Chemical | Low | Not characterised in humans | Injection | Prohibited (S0 catch-all) |
| Eptifibatide Full entry | Peptide | Cardiovascular | FDA Approved | High | ≈ 2.5 hours | Injection | Not on the 2026 List |
| Equine Chorionic Gonadotropin Full entry | Protein, not a peptide | Sexual Health | Veterinary Only | Low | Long (no figure in the abstracts read) | Injection | Prohibited in males, at all times (S2.2.1) |
| Erythropoietin (EPO) Full entry | Protein, not a peptide | Cardiovascular | FDA Approved | High | 4 to 13 hours after IV epoetin alfa (kidney disease); peak 5 to 24 hours after SC | Injection | Prohibited at all times (S2.1.1) |
| Esculentin Full entry | Peptide | Immune | Research Chemical | Low | Very short for the native peptides; engineered long-acting constructs extend it greatly | Not stated | Not on the 2026 List |
| Etelcalcetide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 3.5 days | Injection | Not on the 2026 List |
| Exenatide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 2.4 hours | Injection | Not on the 2026 List |
| FAP-2286 Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Feline Interferon Omega | Protein, not a peptide | Immune | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Felypressin Full entry | Peptide | Cardiovascular | Not FDA Approved | Medium | Short; local activity | Injection | Prohibited at all times (S5) |
| Fexapotide Full entry | Peptide | Research | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| FGL Peptide | Peptide | Cognitive | Research Chemical | Low | Not measured in people | Not stated | Prohibited (S0 catch-all) |
| FK-13 | Peptide | Healing & Recovery | Research Chemical | Medium | Not formally characterized in vivo | Not stated | Prohibited (S0 catch-all) |
| Flotufolastat F 18 Full entry | Not a peptide | Research | FDA Approved | High | Not reported in the sources read | Injection | Not on the 2026 List |
| Fluciclatide Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Follistatin-315 Full entry | Protein, not a peptide | Research | Preclinical | Low | Short; no figure in the sources read | Not stated | Prohibited at all times (S4.3) |
| Follistatin-344 | Protein, not a peptide | Research | Preclinical | Low | Protein; tissue-bound | Injection | Prohibited at all times (S4.3) |
| Follitropin alfa Full entry | Protein, not a peptide | Sexual Health | FDA Approved | High | ≈ 42.6 hours | Injection | Not on the 2026 List |
| Follitropin beta Full entry | Protein, not a peptide | Sexual Health | FDA Approved | High | ≈ 33.4 hours | Injection | Not on the 2026 List |
| Follitropin delta Full entry | Protein, not a peptide | Sexual Health | Not FDA Approved | High | ≈ 55 hours | Injection | Not on the 2026 List |
| Forigerimod Full entry | Peptide | Immune | Not FDA Approved | High | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| FOXO4-DRI | Peptide | Longevity | Preclinical | Low | Not measured in people | Injection | Prohibited (S0 catch-all) |
| FPPRGD2 Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Galacto-RGD Full entry | Peptide | Research | In Clinical Trials | Medium | Not reported in the sources read; over 95% of circulating tracer was still intact at 120 minutes | Injection | Prohibited (S0 catch-all) |
| Galanin Full entry | Peptide | Cognitive | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Galanin-like Peptide (GALP) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Galinpepimut-S | Blend or mixture | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Gallium Ga 68 dotatate Full entry | Peptide conjugate | Research | FDA Approved | High | ≈ 68 minutes | Not stated | Not on the 2026 List |
| Ganirelix Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 12.8 hours | Injection | Not on the 2026 List |
| Garetosmab Full entry | Antibody, not a peptide | Pipeline & In-Development | FDA Approved | Medium | Fc-mediated; weeks | Injection | Prohibited at all times (S4.3) |
| Gastrin Full entry | Peptide | Metabolic | Research Chemical | Low | ≈ 6 minutes | Injection | Prohibited (S0 catch-all) |
| Gastrin-releasing peptide Full entry | Peptide | Metabolic | Research Chemical | Medium | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| GAWK (Chromogranin B 420-493) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous granin peptide | Not stated | Not on the 2026 List |
| GDF11 Full entry | Protein, not a peptide | Longevity | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| GDF15 Full entry | Protein, not a peptide | Longevity | In Clinical Trials | High | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| GHK-Cu Full entry | Peptide | Healing & Recovery | Research Chemical | Medium | Undetermined (systemic) | Injection, Topical or eye | Prohibited (S0 catch-all) |
| Ghrelin Full entry | Peptide | Growth Hormone | Research Chemical | Medium | Not reported in the sources read | Injection | Prohibited at all times (S2.2.4) |
| GHRP-1 | Peptide | Growth Hormone | Research Chemical | Low | Not stated | Not stated | Prohibited at all times (S2.2.4) |
| GHRP-2 Full entry | Peptide | Growth Hormone | Not FDA Approved | Medium | Not reported in humans in the abstracts we hold | Injection | Prohibited at all times (S2.2.4) |
| GHRP-4 | Peptide | Growth Hormone | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited at all times (S2.2.4) |
| GHRP-5 | Peptide | Growth Hormone | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited at all times (S2.2.4) |
| GHRP-6 Full entry | Peptide | Growth Hormone | Research Chemical | Medium | ≈ 2.5 hours | Injection | Prohibited at all times (S2.2.4) |
| GIP Full entry | Peptide | Metabolic | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Glatiramer Acetate Full entry | Not a peptide | Immune | FDA Approved | High | No blood half-life: the label reports that a substantial fraction of each dose is hydrolysed at the injection site | Injection | Not on the 2026 List |
| Glepaglutide Full entry | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Supports twice-weekly dosing | Injection | Prohibited (S0 catch-all) |
| Glicentin Full entry | Protein, not a peptide | Metabolic | Research Chemical | Low | Not stated in the sources read | Not stated | Prohibited (S0 catch-all) |
| GLP-1 Full entry | Peptide | Metabolic | Research Chemical | Medium | ≈ 2.3 minutes | Injection | Unsettled (S0 may apply) |
| GLP-2 Full entry | Peptide | Metabolic | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Glucagon Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 32 minutes | Injection, Nasal | Not on the 2026 List |
| Glutathione Full entry | Peptide | Longevity | Research Chemical | Low | Not reported in the sources read | Oral | Unsettled (S0 may apply) |
| Glypromate | Peptide | Cognitive | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| GMA106 | Protein, not a peptide | Pipeline & In-Development | In Clinical Trials | Low | Not published | Injection | Prohibited (S0 catch-all) |
| GnRF Analogue–Diphtheria Toxoid Conjugate Full entry | Peptide conjugate | Sexual Health | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Gomesin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; natural gomesin is relatively short-lived in serum, while cyclic analogs are markedly more serum-stable | Not stated | Not on the 2026 List |
| Gonadorelin Full entry | Peptide | Sexual Health | Discontinued | Medium | ≈ 5 minutes | Injection | Prohibited in males, at all times (S2.2.1) |
| Gonadorelin (6-D-Phe) | Peptide | Sexual Health | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited in males, at all times (S2.2.1) |
| Goralatide Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not stated | Not stated | Prohibited (S0 catch-all) |
| Goserelin Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 4.2 hours | Injection | Prohibited in males, at all times (S2.2.1) |
| Gozetotide Full entry | Peptidomimetic | Research | FDA Approved | High | Not stated | Injection | Not on the 2026 List |
| Gramicidin Full entry | Peptide | Immune | FDA Approved | High | Topical only | Topical or eye | Not on the 2026 List |
| Growth hormone-releasing hormone Full entry | Peptide | Growth Hormone | Research Chemical | Medium | Not stated in the sources read | Injection | Prohibited at all times (S2.2.4) |
| Guanylin Full entry | Peptide | Metabolic | Research Chemical | Low | Not stated in the sources read | Not stated | Prohibited (S0 catch-all) |
| hBD-1 Full entry | Peptide | Immune | Research Chemical | Low | Not applicable — endogenous epithelial peptide | Not stated | Prohibited (S0 catch-all) |
| hBD-2 Full entry | Peptide | Immune | Research Chemical | Low | Not applicable — endogenous epithelial peptide | Not stated | Prohibited (S0 catch-all) |
| hBD-3 Full entry | Peptide | Immune | Research Chemical | Low | Not applicable — endogenous epithelial peptide | Not stated | Prohibited (S0 catch-all) |
| HCG Full entry | Protein, not a peptide | Growth Hormone | FDA Approved | High | ≈ 29 hours | Injection | Prohibited in males, at all times (S2.2.1) |
| HD5 Full entry | Peptide | Immune | Research Chemical | Low | Not applicable — endogenous epithelial peptide | Not stated | Prohibited (S0 catch-all) |
| HD6 | Peptide | Immune | Research Chemical | Low | Not applicable: made and used locally in the intestinal crypt | Not stated | Prohibited (S0 catch-all) |
| Hemopressin (Hp) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; a hemoglobin-derived peptide | Not stated | Not on the 2026 List |
| Hemorphin (Hemorphins) Full entry | Peptide | Cognitive | Research Chemical | Low | Short; small endogenous peptides, with many stabilised analogs made | Not stated | Not on the 2026 List |
| Hepcidin Full entry | Peptide | Metabolic | Research Chemical | Medium | Not stated | Not stated | Not on the 2026 List |
| Hexanoyl Dipeptide-3 Norleucine Acetate | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Hexapeptide-10 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Hexapeptide-11 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Hexapeptide-33 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Hexapeptide-9 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Hexarelin Full entry | Peptide | Growth Hormone | Research Chemical | Medium | Not measured in humans | Injection | Prohibited at all times (S2.2.4) |
| Histatin Full entry | Peptide | Healing & Recovery | Research Chemical | Medium | Not measured in people in the sources read; broken down by proteases | Not stated | Prohibited (S0 catch-all) |
| Histrelin Full entry | Peptide | Sexual Health | FDA Approved | High | No half-life on the label: the implant keeps serum levels steady through the treatment period | Injection | Prohibited in males, at all times (S2.2.1) |
| HM15136 | Peptide conjugate | Pipeline & In-Development | In Clinical Trials | Low | ≈ 89 hours | Injection | Prohibited (S0 catch-all) |
| HM15275 | Peptide | Pipeline & In-Development | In Clinical Trials | Low | About 110-132 hours (company poster) | Injection | Prohibited (S0 catch-all) |
| HNP-1 Full entry | Peptide | Immune | Research Chemical | Low | Not applicable — endogenous granule-stored peptide | Not stated | Prohibited (S0 catch-all) |
| Homocarnosine Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans; a brain-compartment dipeptide handled within the GABA pathway | Not stated | Not on the 2026 List |
| HRS-9531 | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | 7-8 days (mean, after weekly doses) | Injection | Prohibited (S0 catch-all) |
| Humanin Full entry | Peptide | Longevity | Research Chemical | Low | Not measured in the abstracts we hold | Injection | Prohibited (S0 catch-all) |
| Hyaluronic Acid | Not a peptide | Cosmetic | FDA Approved | High | No single figure: it depends on cross-linking and where it is injected | Injection, Topical or eye | Not on the 2026 List |
| HYNIC-TOC Full entry | Peptide conjugate | Research | Not FDA Approved | Medium | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| Icatibant Full entry | Peptide | Cardiovascular | FDA Approved | High | Not reported in the sources read | Injection | Not on the 2026 List |
| Icotrokinra Full entry | Peptide | Immune | FDA Approved | High | ≈ 12 hours | Oral | Not on the 2026 List |
| IGF-1 Full entry | Peptide | Growth Hormone | FDA Approved | High | ≈ 5.8 hours | Injection | Prohibited at all times (S2.3) |
| IGF-1 DES(1-3) | Peptide | Research | Research Chemical | Low | Minutes to low hours | Injection | Prohibited at all times (S2.3) |
| IGF-1 LR3 Full entry | Protein, not a peptide | Research | Research Chemical | Low | Not measured in people; rats clear it faster than IGF-1 | Injection | Prohibited at all times (S2.3) |
| Indium In 111 pentetreotide Full entry | Peptide conjugate | Research | FDA Approved | High | ≈ 6 hours | Not stated | Not on the 2026 List |
| Indolicidin Full entry | Peptide | Immune | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| INSL3 Full entry | Protein, not a peptide | Sexual Health | Research Chemical | Medium | Not stated | Not stated | Not on the 2026 List |
| INSL5 Full entry | Protein, not a peptide | Metabolic | Research Chemical | Low | Not stated | Not stated | Prohibited (S0 catch-all) |
| Insulin aspart Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | ≈ 81 minutes | Injection | Prohibited at all times (S4.4.2) |
| Insulin degludec Full entry | Peptide | Metabolic | FDA Approved | High | The label gives no half-life; after eight days of once-daily dosing in type 1 diabetes, peak concentration was reached at a median of 9 hours | Injection | Prohibited at all times (S4.4.2) |
| Insulin degludec / liraglutide (IDegLira) Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 25 hours | Injection | Prohibited at all times (S4.4.2) |
| Insulin detemir Full entry | Peptide | Metabolic | Discontinued | High | ≈ 6 hours | Injection | Prohibited at all times (S4.4.2) |
| Insulin efsitora alfa Full entry | Protein, not a peptide | Pipeline & In-Development | FDA Approved | High | ≈ 408 hours | Injection | Prohibited at all times (S4.4.2) |
| Insulin glargine Full entry | Peptide | Metabolic | FDA Approved | High | The label gives no half-life; absorption is slower and more prolonged than NPH, with a relatively constant profile over 24 hours and no pronounced peak | Injection | Prohibited at all times (S4.4.2) |
| Insulin glargine / lixisenatide (iGlarLixi) Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 3 hours | Injection | Prohibited at all times (S4.4.2) |
| Insulin glulisine Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | ≈ 42 minutes | Injection | Prohibited at all times (S4.4.2) |
| Insulin icodec Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | ≈ 7 days | Injection | Prohibited at all times (S4.4.2) |
| Insulin lispro Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | ≈ 1 hour | Injection | Prohibited at all times (S4.4.2) |
| Insulin peglispro Full entry | Protein, not a peptide | Metabolic | Discontinued | High | 44.7 to 75.5 hours at steady state, about 2 to 3 days (PMID 24118909) | Injection | Prohibited at all times (S4.4.2) |
| Insulin tregopil Full entry | Protein, not a peptide | Metabolic | In Clinical Trials | Low | Ultra-fast onset, short action | Oral | Prohibited at all times (S4.4.2) |
| Ipamorelin Full entry | Peptide | Growth Hormone | Research Chemical | Medium | ≈ 2 hours | Injection | Prohibited at all times (S2.2.4) |
| Irisin Full entry | Protein, not a peptide | Metabolic | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Iseganan Full entry | Peptide | Immune | Discontinued | High | Not applicable: not absorbed after oral rinsing | Oral | Prohibited (S0 catch-all) |
| Katacalcin Full entry | Peptide | Research | Research Chemical | Medium | Not stated in the sources read | Not stated | Not on the 2026 List |
| Kisspeptin-10 Full entry | Peptide | Sexual Health | In Clinical Trials | Medium | Short; not established in the studies cited | Injection | Prohibited in males, at all times (S2.2.1) |
| Kisspeptin-54 Full entry | Peptide | Sexual Health | In Clinical Trials | Medium | ≈ 27.6 minutes | Injection | Prohibited in males, at all times (S2.2.1) |
| Klotho Peptide Full entry | Protein, not a peptide | Longevity | Research Chemical | Medium | Not established in people | Not stated | Prohibited (S0 catch-all) |
| KN056 | Protein, not a peptide | Pipeline & In-Development | In Clinical Trials | Low | 141-188 hours (single doses) | Injection | Prohibited (S0 catch-all) |
| KPV Full entry | Peptide | Healing & Recovery | Research Chemical | Low | Not measured | Oral | Prohibited (S0 catch-all) |
| KR-12 | Peptide | Healing & Recovery | Research Chemical | Medium | Not measured | Not stated | Prohibited (S0 catch-all) |
| Kyotorphin Full entry | Peptide | Cognitive | Research Chemical | Low | Broken down rapidly in rodent brain and serum; no human figure | Not stated | Prohibited (S0 catch-all) |
| Lactoferricin | Peptide | Immune | Research Chemical | Medium | Not established in people | Not stated | Prohibited (S0 catch-all) |
| Lancovutide Full entry | Peptide | Research | Not FDA Approved | Medium | About 5 days in bronchial epithelial cells and 25 to 91 days in lavage cells after one inhaled dose | Inhaled | Prohibited (S0 catch-all) |
| Lanreotide Full entry | Peptide | Growth Hormone | FDA Approved | High | ≈ 26 days | Injection | Not on the 2026 List |
| Larazotide Full entry | Peptide | Healing & Recovery | In Clinical Trials | Medium | Not established | Oral | Prohibited (S0 catch-all) |
| Lecirelin | Peptide | Sexual Health | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited in males, at all times (S2.2.1) |
| Leconotide | Peptide | Cognitive | Not FDA Approved | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Lepirudin Full entry | Protein, not a peptide | Cardiovascular | Discontinued | High | ≈ 1.3 hours | Injection | Unsettled (S0 may apply) |
| Leuphasyl | Peptide | Cosmetic | Research Chemical | Low | Topical only | Topical or eye | Unsettled (S0 may apply) |
| Leuprolide Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 3 hours | Injection | Prohibited in males, at all times (S2.2.1) |
| Linaclotide Full entry | Peptide | Healing & Recovery | FDA Approved | High | Not systemically absorbed; acts luminally | Oral | Not on the 2026 List |
| Liraglutide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 13 hours | Injection | Not on the 2026 List |
| Livagen | Peptide | Longevity | Research Chemical | Low | Undetermined | Oral | Prohibited (S0 catch-all) |
| Livoletide | Peptide | Metabolic | Discontinued | Low | 2-3 hours | Injection | Prohibited (S0 catch-all) |
| Lixisenatide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 3 hours | Injection | Not on the 2026 List |
| Lixivaptan Full entry | Small molecule, not a peptide | Cardiovascular | Discontinued | Medium | Not reported in the sources read | Oral | Prohibited at all times (S5) |
| LL-37 Full entry | Peptide | Healing & Recovery | Research Chemical | Low | Undetermined | Injection, Topical or eye | Prohibited (S0 catch-all) |
| Lonapegsomatropin Full entry | Protein, not a peptide | Growth Hormone | FDA Approved | High | ≈ 30.7 hours | Injection | Prohibited at all times (S2.2.3) |
| LSALT peptide | Peptide | Pipeline & In-Development | In Clinical Trials | Low | ≈ 0.41 hours | Injection | Prohibited (S0 catch-all) |
| Lucinactant Full entry | Blend or mixture | Research | Discontinued | High | Not studied in people | Not stated | Unsettled (S0 may apply) |
| Lunasin Full entry | Peptide | Research | Research Chemical | Low | Not reported in the sources read | Not stated | Not on the 2026 List |
| Lusupultide Full entry | Peptide | Research | Not FDA Approved | Medium | About 11 hours from rabbit lungs; 28 hours in mice | Not stated | Prohibited (S0 catch-all) |
| Lutetium-177 DOTATATE Full entry | Peptide conjugate | Research | FDA Approved | High | ≈ 71 hours | Injection | Not on the 2026 List |
| Lutropin alfa Full entry | Protein, not a peptide | Sexual Health | Discontinued | Medium | 10 to 12 hours (terminal) | Injection | Prohibited in males, at all times (S2.2.1) |
| Lypressin Full entry | Peptide | Metabolic | Discontinued | Low | Not stated | Not stated | Unsettled (S0 may apply) |
| Macimorelin Full entry | Peptidomimetic | Growth Hormone | FDA Approved | High | ≈ 4.1 hours | Oral | Prohibited at all times (S2.2.4) |
| Magainin | Peptide | Immune | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Manserin Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans as a drug; an endogenous granin peptide | Not stated | Not on the 2026 List |
| Maraciclatide Full entry | Peptide | Research | In Clinical Trials | Medium | ≈ 1 hour | Injection | Prohibited (S0 catch-all) |
| Maridebart cafraglutide | Peptide conjugate | Pipeline & In-Development | In Clinical Trials | Medium | Not reported in the abstracts read; dosed every 4 or 8 weeks in phase 2 | Injection | Prohibited (S0 catch-all) |
| Mastoparan Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a membrane-active venom peptide used as a research tool | Not stated | Not on the 2026 List |
| Mazdutide Full entry | Peptide | Metabolic | Not FDA Approved | High | Not reported in the sources read; dosed once weekly | Injection | Unsettled (S0 may apply) |
| Mecasermin Full entry | Peptide | Growth Hormone | FDA Approved | High | The label gives no half-life; it reports bioavailability close to 100% after subcutaneous dosing in healthy subjects, and that over 80% of circulating IGF-1 is bound in a complex with IGFBP-3 | Injection | Prohibited at all times (S2.3) |
| Mecasermin rinfabate Full entry | Protein, not a peptide | Growth Hormone | Discontinued | Medium | ≈ 21 hours | Injection | Prohibited at all times (S2.3) |
| Melanin-concentrating hormone Full entry | Peptide | Metabolic | Research Chemical | Medium | Not stated in the sources read | Not stated | Prohibited (S0 catch-all) |
| Melanocyte-stimulating hormone beta Full entry | Peptide | Metabolic | Research Chemical | Medium | Not stated in the sources read | Not stated | Prohibited (S0 catch-all) |
| Melanotan II Full entry | Peptide | Sexual Health | Research Chemical | Medium | Not measured in humans | Injection | Prohibited (S0 catch-all) |
| Melatonin Full entry | Small molecule, not a peptide | Longevity | Dietary Supplement | Medium | About 1 hour; 1.6 hours extended-release | Oral, Topical or eye | Not on the 2026 List |
| Melittin Full entry | Peptide | Immune | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Melphalan Flufenamide Full entry | Peptide conjugate | Research | Not FDA Approved | High | ≈ 2.1 minutes | Injection | Not on the 2026 List |
| Menotropin Full entry | Protein, not a peptide | Sexual Health | FDA Approved | High | ≈ 12 hours | Injection | Prohibited in males, at all times (S2.2.1) |
| Metreleptin Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | 3.8 to 4.7 hours | Injection | Not on the 2026 List |
| MGF | Peptide | Research | Research Chemical | Low | Shorter than systemic IGF-1's when unbound; not measured in people | Not stated | Prohibited at all times (S2.3) |
| Micafungin Full entry | Peptide | Immune | FDA Approved | High | ≈ 13.4 hours | Not stated | Not on the 2026 List |
| Mifamurtide Full entry | Peptide conjugate | Immune | Not FDA Approved | High | Not stated | Not stated | Not on the 2026 List |
| MK-677 Full entry | Small molecule, not a peptide | Growth Hormone | Research Chemical | Medium | Not reported in the abstracts we hold | Oral | Prohibited at all times (S2.2.4) |
| Mod GRF 1-29 | Peptide | Growth Hormone | Research Chemical | Low | Not measured in humans | Injection | Prohibited at all times (S2.2.4) |
| Modimelanotide Full entry | Peptide | Immune | Discontinued | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Montirelin | Peptide | Cognitive | Discontinued | Low | Longer-acting than TRH; no human pharmacokinetic value published | Not stated | Prohibited (S0 catch-all) |
| Morphiceptin Full entry | Peptide | Cognitive | Research Chemical | Low | Short; a small peptide degraded by brain and tissue peptidases | Not stated | Not on the 2026 List |
| Motilin Full entry | Peptide | Metabolic | Research Chemical | Low | ≈ 4.6 minutes | Injection | Prohibited (S0 catch-all) |
| Motixafortide Full entry | Peptide | Immune | FDA Approved | High | ≈ 2 hours | Injection | Not on the 2026 List |
| MOTS-c Full entry | Peptide | Longevity | Research Chemical | Low | Undetermined in humans | Injection | Prohibited at all times (S4.4.1) |
| Murabutide Full entry | Peptide conjugate | Immune | Not FDA Approved | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Muramyl Dipeptide Full entry | Peptide conjugate | Immune | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Murepavadin Full entry | Peptidomimetic | Immune | In Clinical Trials | Medium | 2.5–5.3 hours (single intravenous doses, healthy men); 7.7 hours in a renal study's normal-function group | Injection | Prohibited (S0 catch-all) |
| Myristoyl Hexapeptide-16 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Myristoyl Pentapeptide-17 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Myristoyl Tetrapeptide-12 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| NA-Selank Amidate | Peptide | Cognitive | Research Chemical | Low | Not measured | Nasal | Prohibited (S0 catch-all) |
| NAD+ Full entry | Small molecule, not a peptide | Longevity | Research Chemical | Medium | Not reported in the abstracts we hold | Injection | Unsettled (S0 may apply) |
| Nafarelin Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 3 hours | Nasal | Prohibited in males, at all times (S2.2.1) |
| Nangibotide Full entry | Peptide | Immune | In Clinical Trials | Medium | ≈ 3 minutes | Injection | Prohibited (S0 catch-all) |
| Navepegritide Full entry | Peptide conjugate | Growth Hormone | FDA Approved | High | ≈ 6.7 days | Injection | Not on the 2026 List |
| Nelipepimut-S Full entry | Peptide | Research | In Clinical Trials | High | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Nemifitide Full entry | Peptide | Cognitive | Discontinued | Medium | 15–30 minutes (subcutaneous, most subjects) | Injection | Prohibited (S0 catch-all) |
| Nendratareotide Uzatansine | Peptide conjugate | Research | Not FDA Approved | Low | Not reported in any journal paper; see the trial registry figures under Molecular Data | Injection | Prohibited (S0 catch-all) |
| NeoB Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | ≈ 27.3 minutes | Injection | Prohibited (S0 catch-all) |
| Nerinetide Full entry | Peptide | Cognitive | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| NERP-2 (Neuroendocrine Regulatory Peptide-2) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; endogenous VGF-derived peptides | Not stated | Not on the 2026 List |
| Nesfatin-1 Full entry | Protein, not a peptide | Metabolic | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Nesiritide Full entry | Peptide | Cardiovascular | Discontinued | High | About 18 minutes | Injection | Unsettled (S0 may apply) |
| Neurokinin A Full entry | Peptide | Immune | Research Chemical | Medium | Not stated in the sources read | Injection, Inhaled | Prohibited (S0 catch-all) |
| Neurokinin B Full entry | Peptide | Sexual Health | Research Chemical | Medium | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Neuromedin B Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans; an endogenous, locally acting neuropeptide | Not stated | Not on the 2026 List |
| Neuromedin N (NN) Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide, rapidly degraded | Not stated | Not on the 2026 List |
| Neuromedin S Full entry | Peptide | Cognitive | Research Chemical | Low | Not stated | Not stated | Prohibited (S0 catch-all) |
| Neuromedin U Full entry | Peptide | Metabolic | Research Chemical | Medium | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Neuropeptide AF (NPAF) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous neuropeptide | Not stated | Not on the 2026 List |
| Neuropeptide B (NPB) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Neuropeptide EI (NEI) Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans as a drug; an endogenous neuropeptide | Not stated | Not on the 2026 List |
| Neuropeptide FF (NPFF) Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Neuropeptide S Full entry | Peptide | Cognitive | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Neuropeptide W (NPW) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Neuropeptide Y Full entry | Peptide | Cognitive | Research Chemical | Medium | No figure in the sources read; the 2022 exercise study reports it is considerably shorter than immunoassays had established | Not stated | Prohibited (S0 catch-all) |
| Neurotensin Full entry | Peptide | Cognitive | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Nisin | Peptide | Immune | Food Additive Only | High | Not reported in the sources read; it is eaten rather than injected | Not stated | Not on the 2026 List |
| Nociceptin Full entry | Peptide | Cognitive | Research Chemical | Low | Not reported in people | Not stated | Prohibited (S0 catch-all) |
| Nocistatin (NST) Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| NODAGA-exendin-4 Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Nonapeptide-1 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Noopept Full entry | Peptidomimetic | Cognitive | Not FDA Approved | Medium | No figure in the abstracts read; eliminated more slowly in people than in rats or rabbits | Oral | Unsettled (S0 may apply) |
| Nosiheptide | Peptide | Immune | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| NPAS3 Research Peptide | Peptide | Cognitive | Research Chemical | Low | Not reported | Not stated | Prohibited (S0 catch-all) |
| NPH insulin (isophane) Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | ≈ 4.4 hours | Injection | Prohibited at all times (S4.4.2) |
| Obestatin Full entry | Peptide | Metabolic | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Obinepitide | Peptide | Pipeline & In-Development | In Clinical Trials | Low | Not published | Injection | Prohibited (S0 catch-all) |
| Octapeptide-2 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Octreotide Full entry | Peptide | Growth Hormone | FDA Approved | High | ≈ 1.8 hours | Injection | Not on the 2026 List |
| Olatorepatide | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Not published | Injection | Prohibited (S0 catch-all) |
| Oligopeptide-68 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Omiganan Full entry | Peptide | Healing & Recovery | Discontinued | High | Not established (topical gel only) | Topical or eye | Prohibited (S0 catch-all) |
| Oncocin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a short linear peptide, analogs engineered for protease stability | Not stated | Not on the 2026 List |
| Opiorphin Full entry | Peptide | Cognitive | Research Chemical | Low | Very short; the natural peptide is rapidly degraded, motivating stabilized analogs (STR-324) | Not stated | Not on the 2026 List |
| Orexin-A Full entry | Peptide | Cognitive | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Orexin-B | Peptide | Cognitive | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Orforglipron Full entry | Small molecule, not a peptide | Metabolic | FDA Approved | Medium | ≈ 39 hours | Oral | Not on the 2026 List |
| Oritavancin Full entry | Peptide | Immune | FDA Approved | High | ≈ 245 hours | Injection | Not on the 2026 List |
| Ornipressin Full entry | Peptide | Cardiovascular | Not FDA Approved | Medium | Not stated in the sources read | Injection | Unsettled (S0 may apply) |
| Osteocalcin Full entry | Peptide | Healing & Recovery | Research Chemical | Low | Not stated in the sources read | Not stated | Prohibited (S0 catch-all) |
| Osteogenic growth peptide | Peptide | Healing & Recovery | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Ovagen | Peptide | Longevity | Research Chemical | Low | Undetermined | Oral | Prohibited (S0 catch-all) |
| Oxyntomodulin Full entry | Peptide | Metabolic | Research Chemical | Medium | ≈ 12 minutes | Not stated | Prohibited (S0 catch-all) |
| Oxytocin Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 3 minutes | Nasal | Not on the 2026 List |
| Ozarelix | Peptide | Sexual Health | Not FDA Approved | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| P21 | Peptidomimetic | Cognitive | Research Chemical | Low | Not established in human studies | Not stated | Prohibited (S0 catch-all) |
| PACAP Full entry | Peptide | Cognitive | Research Chemical | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Pal-GHK | Peptide | Cosmetic | Research Chemical | Medium | Topical only | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Dipeptide-10 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Dipeptide-5 Diaminohydroxybutyrate | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Dipeptide-7 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Hexapeptide-12 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Hexapeptide-14 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Pentapeptide-4 | Peptide | Cosmetic | Research Chemical | Medium | Topical only; not a systemic drug | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Tetrapeptide-10 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Tetrapeptide-20 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Tetrapeptide-7 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Tripeptide-28 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Tripeptide-38 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Tripeptide-5 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palmitoyl Tripeptide-8 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Palopegteriparatide Full entry | Peptide conjugate | Healing & Recovery | FDA Approved | High | ≈ 60 hours | Injection | Not on the 2026 List |
| PAMP (Proadrenomedullin N-terminal 20 Peptide) Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not established for humans as a drug; an endogenous precursor peptide | Not stated | Not on the 2026 List |
| Pancragen | Peptide | Metabolic | Research Chemical | Low | Not stated | Not stated | Prohibited (S0 catch-all) |
| Pancreastatin Full entry | Peptide | Metabolic | Research Chemical | Medium | Not established for humans as a drug; an endogenous circulating peptide | Injection | Not on the 2026 List |
| Pancreatic polypeptide Full entry | Peptide | Metabolic | Research Chemical | Medium | ≈ 6.9 minutes | Injection | Prohibited (S0 catch-all) |
| Parathyroid hormone (1-84) Full entry | Protein, not a peptide | Healing & Recovery | Discontinued | High | ≈ 3 hours | Injection | Unsettled (S0 may apply) |
| Parathyroid hormone-related protein Full entry | Protein, not a peptide | Healing & Recovery | Research Chemical | Medium | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Pasireotide Full entry | Peptide | Growth Hormone | FDA Approved | High | Not reported in the sources read | Injection | Not on the 2026 List |
| PB-718 | Peptide | Pipeline & In-Development | In Clinical Trials | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| PE-22-28 | Peptide | Cognitive | Research Chemical | Low | Undetermined in humans | Not stated | Prohibited (S0 catch-all) |
| Peforelin Full entry | Peptide | Sexual Health | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited in males, at all times (S2.2.1) |
| PEG-MGF | Peptide | Research | Research Chemical | Low | Not measured: no pharmacokinetic study of PEG-MGF exists | Not stated | Prohibited at all times (S2.3) |
| Pegbelfermin Full entry | Protein, not a peptide | Pipeline & In-Development | Discontinued | Medium | Weekly dosing | Injection | Unsettled (S2.3 may apply) |
| Pegbovigrastim Full entry | Protein, not a peptide | Immune | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Pegcetacoplan Full entry | Peptide conjugate | Immune | FDA Approved | High | ≈ 8.6 days | Injection | Not on the 2026 List |
| Peginesatide Full entry | Peptide | Cardiovascular | Discontinued | High | ≈ 47.9 hours | Injection | Prohibited at all times (S2.1.1) |
| Pegmolesatide Full entry | Peptide conjugate | Cardiovascular | Not FDA Approved | Medium | Long (dosed every four weeks); no figure in the sources read | Injection | Prohibited at all times (S2.1.1) |
| Pegozafermin | Protein, not a peptide | Pipeline & In-Development | In Clinical Trials | Medium | 55 to 100 hours (PMID 37562970) | Injection | Unsettled (S2.3 may apply) |
| Pegsebrenatide Full entry | Peptide conjugate | Cognitive | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Pegvisomant Full entry | Protein, not a peptide | Growth Hormone | FDA Approved | High | 60 to 138 hours (mean estimates after single or multiple doses) | Injection | Unsettled (S2.2.3 may apply) |
| Pemvidutide | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Not reported; dosed once weekly in trials | Injection | Prohibited (S0 catch-all) |
| Pentagastrin Full entry | Peptide | Metabolic | Discontinued | Medium | Not stated | Not stated | Unsettled (S0 may apply) |
| Pentapeptide-3 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Pentapeptide-31 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Pentigetide (IgE Pentapeptide) Full entry | Peptide | Immune | Research Chemical | Medium | Not established; a short synthetic pentapeptide given topically in trials | Nasal, Topical or eye | Not on the 2026 List |
| Pentixafor Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Pentixather Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| PEPITEM | Peptide | Immune | Preclinical | Low | Not stated | Not stated | Prohibited (S0 catch-all) |
| Peptide YY Full entry | Peptide | Metabolic | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Petrelintide | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Engineered for once-weekly dosing | Injection | Prohibited (S0 catch-all) |
| Pexiganan Full entry | Peptide | Healing & Recovery | Discontinued | High | Topical; minimal systemic absorption | Topical or eye | Prohibited (S0 catch-all) |
| PHM-27 Full entry | Peptide | Metabolic | Research Chemical | Low | Not stated | Injection | Prohibited (S0 catch-all) |
| Phoenixin Full entry | Peptide | Sexual Health | Research Chemical | Low | Not established for humans; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Piflufolastat F 18 Full entry | Small molecule, not a peptide | Research | FDA Approved | High | ≈ 3.47 hours | Injection | Not on the 2026 List |
| Pinealon | Peptide | Longevity | Research Chemical | Low | Undetermined | Oral | Prohibited (S0 catch-all) |
| Piscidin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; short cationic peptides, variable stability | Not stated | Not on the 2026 List |
| Plantaricin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; small heat-stable bacteriocins, stable across pH and heat in food systems | Not stated | Not on the 2026 List |
| Plecanatide Full entry | Peptide | Healing & Recovery | FDA Approved | High | Not systemically absorbed; acts luminally | Oral | Not on the 2026 List |
| Plectasin | Peptide | Immune | Preclinical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Pleurocidin Full entry | Peptide | Immune | Research Chemical | Low | Short and delivery-limited in the body; stereochemistry and formulation strongly affect exposure | Not stated | Not on the 2026 List |
| Plitidepsin Full entry | Peptide | Research | Not FDA Approved | Medium | 21 to 44 hours in plasma | Injection | Not on the 2026 List |
| PNC-27 | Peptide | Research | Preclinical | Low | Not established | Not stated | Prohibited (S0 catch-all) |
| Polaprezinc Full entry | Peptide conjugate | Healing & Recovery | Not FDA Approved | High | Not stated in the sources read | Oral | Not on the 2026 List |
| Polyethylene glycol loxenatide Full entry | Peptide conjugate | Metabolic | Not FDA Approved | High | ≈ 121 hours | Injection | Unsettled (S0 may apply) |
| Polymyxin B Full entry | Peptide | Immune | FDA Approved | High | ≈ 4.1 hours | Injection | Not on the 2026 List |
| Ponericin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a short linear peptide, engineered analogs improve stability | Not stated | Not on the 2026 List |
| Porcine FSH Full entry | Protein, not a peptide | Sexual Health | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Porcine Insulin Zinc Suspension Full entry | Protein, not a peptide | Metabolic | Veterinary Only | Medium | Not reported in the sources read | Injection | Prohibited at all times (S4.4.2) |
| Posatirelin Full entry | Peptide | Cognitive | Discontinued | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Pramlintide Full entry | Peptide | Metabolic | Discontinued | High | ≈ 48 minutes | Injection | Unsettled (S0 may apply) |
| Preptin Full entry | Peptide | Metabolic | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Prokineticin 1 (EG-VEGF) Full entry | Peptide | Sexual Health | Research Chemical | Low | Not established for humans as a drug; an endogenous circulating peptide | Not stated | Not on the 2026 List |
| Prokineticin 2 Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Prolactin-releasing peptide Full entry | Peptide | Metabolic | Research Chemical | Low | Not stated in the sources read | Not stated | Not on the 2026 List |
| Prolyl-Hydroxyproline Full entry | Peptide | Research | Research Chemical | Low | Not reported in the sources read | Not stated | Not on the 2026 List |
| Prostamax | Peptide | Longevity | Not FDA Approved | Low | Not characterized in humans | Oral | Prohibited (S0 catch-all) |
| Prostatilen Full entry | Blend or mixture | Longevity | Not FDA Approved | Low | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| Protegrin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a disulfide-stabilised beta-hairpin, more protease-resistant than linear AMPs | Not stated | Not on the 2026 List |
| Protirelin Full entry | Peptide | Growth Hormone | Discontinued | High | Not reported in the abstracts read | Injection | Prohibited (S0 catch-all) |
| PSMA I&S Full entry | Not a peptide | Research | In Clinical Trials | Medium | ≈ 4.15 hours | Injection | Prohibited (S0 catch-all) |
| PSMA-1007 Full entry | Not a peptide | Research | Not FDA Approved | Medium | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| PT-141 Full entry | Peptide | Sexual Health | FDA Approved | High | ≈ 2.7 hours | Injection | Not on the 2026 List |
| QRFP (26RFa) Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans; an endogenous, centrally acting neuropeptide | Not stated | Not on the 2026 List |
| Ramoplanin Full entry | Peptide | Immune | Discontinued | Medium | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| Recombinant Human Endostatin Full entry | Protein, not a peptide | Research | Not FDA Approved | Medium | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| Regular human insulin Full entry | Protein, not a peptide | Metabolic | FDA Approved | High | ≈ 1.5 hours | Injection | Prohibited at all times (S4.4.2) |
| Relamorelin Full entry | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Not reported in the abstracts read | Injection | Prohibited at all times (S2.2.4) |
| Relaxin-3 Full entry | Protein, not a peptide | Cognitive | Research Chemical | Low | Not stated | Not stated | Prohibited (S0 catch-all) |
| Relugolix Full entry | Small molecule, not a peptide | Sexual Health | FDA Approved | High | ≈ 61 hours | Oral | Not on the 2026 List |
| Retatrutide Full entry | Peptide | Metabolic | In Clinical Trials | Medium | ≈ 6 days | Injection | Prohibited (S0 catch-all) |
| Retinalamin Full entry | Blend or mixture | Longevity | Not FDA Approved | Low | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| Rezafungin Full entry | Peptide | Immune | FDA Approved | High | ≈ 152 hours | Injection | Not on the 2026 List |
| RFRP-3 (GnIH) Full entry | Peptide | Sexual Health | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| RM2 Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Romidepsin Full entry | Peptide | Research | FDA Approved | High | ≈ 3 hours | Injection | Not on the 2026 List |
| Romiplostim Full entry | Protein, not a peptide | Immune | FDA Approved | High | Not reported in the sources read | Injection | Not on the 2026 List |
| Romurtide Full entry | Peptide conjugate | Immune | Not FDA Approved | Medium | ≈ 2.7 hours | Injection | Unsettled (S0 may apply) |
| Rotigaptide Full entry | Peptide | Cardiovascular | Discontinued | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Rovatirelin | Peptidomimetic | Cognitive | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Rubiscolin Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans; a small food-derived peptide, unusually active after oral dosing in mice | Not stated | Not on the 2026 List |
| Rusalatide Full entry | Peptide | Healing & Recovery | Not FDA Approved | Low | Short; no figure in the abstracts read (a 30 kDa PEG derivative lasted about 19 times longer in mice) | Topical or eye | Prohibited (S0 catch-all) |
| Rusfertide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 28.6 hours | Injection | Not on the 2026 List |
| Ruxotemitide Full entry | Peptide | Research | In Clinical Trials | Low | 160 minutes in human plasma in a test tube; no in-body half-life in the abstracts read | Oral | Prohibited (S0 catch-all) |
| Salusin-alpha Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not stated in the sources read | Not stated | Not on the 2026 List |
| Salusin-beta Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not stated in the sources read | Not stated | Not on the 2026 List |
| SAR-bisPSMA | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| SARTATE | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Satoreotide Tetraxetan Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | ≈ 127 hours | Injection | Prohibited (S0 catch-all) |
| Satoreotide Trizoxetan Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Secretin Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 45 minutes | Injection | Not on the 2026 List |
| Secretoneurin (SN) Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not established for humans as a drug; an endogenous circulating peptide | Not stated | Not on the 2026 List |
| Seglitide Full entry | Peptide | Pipeline & In-Development | Discontinued | Medium | About 45 minutes in people (vs ~2 minutes for somatostatin) | Injection | Prohibited (S0 catch-all) |
| Selank Full entry | Peptide | Cognitive | Not FDA Approved | Medium | Not measured in humans | Nasal | Unsettled (S0 may apply) |
| Selepressin | Peptide | Cardiovascular | Discontinued | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Semaglutide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 7 days | Injection, Oral | Not on the 2026 List |
| Semax Full entry | Peptide | Cognitive | Not FDA Approved | Medium | Not measured in humans | Nasal | Unsettled (S0 may apply) |
| Serelaxin Full entry | Protein, not a peptide | Cardiovascular | Discontinued | High | Mean terminal half-life about 7 to 8 hours after a 24-hour infusion (PMID 25511105) | Injection | Prohibited (S0 catch-all) |
| Sermorelin Full entry | Peptide | Growth Hormone | Discontinued | Medium | Not established in our sources | Injection | Prohibited at all times (S2.2.4) |
| Serpinin Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Setmelanotide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 11 hours | Injection | Not on the 2026 List |
| SHLP2 | Peptide | Longevity | Research Chemical | Medium | Not formally characterized in humans | Not stated | Prohibited (S0 catch-all) |
| SHLP6 | Peptide | Longevity | Research Chemical | Low | Not formally characterized | Not stated | Prohibited (S0 catch-all) |
| Sialorphin Full entry | Peptide | Cognitive | Research Chemical | Low | Short; a small peptide, with lipidated analogs made to improve stability | Not stated | Not on the 2026 List |
| SiTATE Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Snakin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; disulfide-stabilised and notably heat-stable | Not stated | Not on the 2026 List |
| Solnatide Full entry | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Not reported in the sources read | Inhaled | Prohibited (S0 catch-all) |
| Somapacitan Full entry | Protein, not a peptide | Growth Hormone | FDA Approved | High | ≈ 60 hours | Injection | Prohibited at all times (S2.2.3) |
| Somatostatin Full entry | Peptide | Growth Hormone | Not FDA Approved | High | A few minutes in plasma, which is why it is given by continuous infusion | Not stated | Not on the 2026 List |
| Somatrem Full entry | Protein, not a peptide | Growth Hormone | Discontinued | Medium | ≈ 3 hours | Injection | Prohibited at all times (S2.2.3) |
| Somatrogon Full entry | Protein, not a peptide | Growth Hormone | FDA Approved | High | ≈ 37.7 hours | Injection | Prohibited at all times (S2.2.3) |
| Somatropin (HGH) Full entry | Protein, not a peptide | Growth Hormone | FDA Approved | High | ≈ 3.5 hours | Injection | Prohibited at all times (S2.2.3) |
| Sometribove Full entry | Protein, not a peptide | Growth Hormone | Veterinary Only | Low | Not reported in the sources read | Injection | Prohibited at all times (S2.2.3) |
| Sonefpeglutide | Peptide | Pipeline & In-Development | In Clinical Trials | Low | Not reported in people | Injection | Prohibited (S0 catch-all) |
| Sotatercept Full entry | Protein, not a peptide | Cardiovascular | FDA Approved | High | ≈ 24 days | Injection | Prohibited at all times (S2.1.4) |
| Sovateltide Full entry | Peptide | Cognitive | Not FDA Approved | Medium | Not stated | Not stated | Not on the 2026 List |
| Spexin Full entry | Peptide | Metabolic | Research Chemical | Low | Not characterised in people | Not stated | Prohibited (S0 catch-all) |
| Spinorphin Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans; a small endogenous peptide | Not stated | Not on the 2026 List |
| SS-31 (Elamipretide) Full entry | Peptide | Longevity | FDA Approved | High | Not stated on the FORZINITY label | Injection | Not on the 2026 List |
| Substance P Full entry | Peptide | Immune | Research Chemical | Medium | Not measured in people in the sources read | Not stated | Prohibited (S0 catch-all) |
| Surotomycin Full entry | Peptide | Immune | Discontinued | High | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| Survodutide Full entry | Peptide | Metabolic | In Clinical Trials | High | Long enough for weekly dosing; not reported in the abstracts we hold | Injection | Prohibited (S0 catch-all) |
| Syn-Ake | Peptidomimetic | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Tabimorelin | Small molecule, not a peptide | Pipeline & In-Development | Discontinued | Low | Not reported in the sources read | Oral | Prohibited at all times (S2.2.4) |
| Tachyplesin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; a disulfide-stabilised peptide is more protease-resistant than linear AMPs | Not stated | Not on the 2026 List |
| Taldefgrobep alfa | Protein, not a peptide | Pipeline & In-Development | In Clinical Trials | Medium | Not stated | Injection | Prohibited at all times (S4.3) |
| Taltirelin Full entry | Peptidomimetic | Cognitive | Not FDA Approved | Medium | Not stated | Oral | Unsettled (S0 may apply) |
| Taspoglutide Full entry | Peptide | Pipeline & In-Development | Discontinued | High | Not reported in people in the sources read | Injection | Prohibited (S0 catch-all) |
| TB-500 Full entry | Peptide | Healing & Recovery | Research Chemical | Low | Undetermined in humans | Injection | Prohibited at all times (S2.3) |
| TCAP-1 (Teneurin C-terminal Associated Peptide-1) Full entry | Peptide | Cognitive | Research Chemical | Low | Not established for humans as a drug; a teneurin-derived peptide | Not stated | Not on the 2026 List |
| Tecemotide Full entry | Peptide | Research | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Technetium Tc 99m Apcitide Full entry | Peptide | Research | Discontinued | Medium | ≈ 2 hours | Injection | Not on the 2026 List |
| Technetium Tc 99m Etarfolatide Full entry | Not a peptide | Research | Discontinued | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Technetium Tc 99m mertiatide Full entry | Peptide conjugate | Research | FDA Approved | High | No elimination half-life stated on the label: nearly 90% of the dose is in urine within 3 hours in healthy subjects (plasma clearance about 0.3 L/min); technetium-99m decays with a 6.02-hour physical half-life | Injection | Not on the 2026 List |
| Teduglutide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 1.3 hours | Injection | Not on the 2026 List |
| Teicoplanin Full entry | Peptide | Immune | Not FDA Approved | High | Not stated | Not stated | Not on the 2026 List |
| Teixobactin | Peptide | Immune | Preclinical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Telavancin Full entry | Peptide | Immune | FDA Approved | High | ≈ 8 hours | Not stated | Not on the 2026 List |
| Temporin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; short cationic/hydrophobic peptides subject to proteolysis | Not stated | Not on the 2026 List |
| Teprotide Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Teriparatide Full entry | Peptide | Healing & Recovery | FDA Approved | High | ≈ 1 hour | Injection | Not on the 2026 List |
| Terlipressin Full entry | Peptide | Cardiovascular | FDA Approved | High | ≈ 0.9 hours | Injection | Unsettled (S5 may apply) |
| Tertomotide Full entry | Peptide | Research | Not FDA Approved | High | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| Tesamorelin Full entry | Peptide | Growth Hormone | FDA Approved | High | 8–11 minutes (current labels) | Injection | Prohibited at all times (S2.2.4) |
| Tesofensine Full entry | Small molecule, not a peptide | Research | In Clinical Trials | Medium | ≈ 234 hours | Oral | Prohibited in competition (S6.B) |
| Testagen | Peptide | Longevity | Not FDA Approved | Low | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| Tetracosactide Full entry | Peptide | Growth Hormone | FDA Approved | High | Not stated | Injection | Prohibited at all times (S2.2.2) |
| Tetrapeptide-1 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Tetrapeptide-21 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Tetrapeptide-26 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Tetrapeptide-30 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Teverelix Full entry | Peptide | Sexual Health | In Clinical Trials | Medium | 24-75 hours after single 0.5-5 mg doses; depot release from large doses | Injection | Prohibited (S0 catch-all) |
| Thionin Full entry | Peptide | Immune | Research Chemical | Low | Not established for humans; disulfide-stabilised and relatively stable | Not stated | Not on the 2026 List |
| Thiostrepton Full entry | Peptide | Immune | Research Chemical | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Thrombomodulin Alfa Full entry | Protein, not a peptide | Cardiovascular | Not FDA Approved | High | ≈ 20 hours | Injection | Unsettled (S0 may apply) |
| Thymalin Full entry | Blend or mixture | Longevity | Not FDA Approved | Low | Not established | Injection | Unsettled (S0 may apply) |
| Thymoctonan | Peptide | Immune | Discontinued | Low | Under 6 minutes in human whole blood at 37 °C (2020) | Injection | Prohibited (S0 catch-all) |
| Thymodepressin Full entry | Peptide | Immune | Not FDA Approved | Low | Not reported in the sources read | Injection | Unsettled (S0 may apply) |
| Thymogen Full entry | Peptide | Longevity | Not FDA Approved | Low | Not reported in the abstracts read | Injection, Nasal | Unsettled (S0 may apply) |
| Thymomodulin Full entry | Blend or mixture | Immune | Not FDA Approved | Medium | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| Thymopentin Full entry | Peptide | Immune | Not FDA Approved | Medium | Extremely short in the body; not measured in people in the sources read | Injection | Prohibited (S0 catch-all) |
| Thymosin α1 Full entry | Peptide | Immune | Not FDA Approved | High | ≈ 2 hours | Injection | Unsettled (S0 may apply) |
| Thymosin β4 Full entry | Peptide | Healing & Recovery | In Clinical Trials | Medium | Not reported in the abstracts we hold | Topical or eye | Prohibited at all times (S2.3) |
| Thymostimulin Full entry | Blend or mixture | Immune | Not FDA Approved | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Thymulin Full entry | Peptide | Immune | Research Chemical | Low | About 10 minutes in sheep; not measured in people | Injection | Prohibited (S0 catch-all) |
| Thyrotropin alfa Full entry | Protein, not a peptide | Growth Hormone | FDA Approved | High | ≈ 25 hours | Injection | Not on the 2026 List |
| Tifuvirtide Full entry | Peptide | Immune | Discontinued | Medium | Not stated | Injection | Prohibited (S0 catch-all) |
| Tiplimotide | Peptide | Immune | Not FDA Approved | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Tirzepatide Full entry | Peptide | Metabolic | FDA Approved | High | ≈ 5 days | Injection | Not on the 2026 List |
| TLQP-21 Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous VGF-derived peptide | Not stated | Not on the 2026 List |
| Tozuleristide Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | ≈ 30 minutes | Injection | Prohibited (S0 catch-all) |
| Trafermin Full entry | Protein, not a peptide | Healing & Recovery | Not FDA Approved | High | Not stated as a figure in the sources read | Topical or eye | Prohibited at all times (S2.3) |
| Trevogrumab | Antibody, not a peptide | Pipeline & In-Development | In Clinical Trials | Low | Not reported in the sources read | Injection | Prohibited at all times (S4.3) |
| Trifluoroacetyl Tripeptide-2 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Tripeptide-10 Citrulline | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Tripeptide-29 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Oral, Topical or eye | Unsettled (S0 may apply) |
| Tripeptide-32 | Peptide | Cosmetic | Research Chemical | Low | Not reported in the sources read | Topical or eye | Unsettled (S0 may apply) |
| Triptorelin Full entry | Peptide | Sexual Health | FDA Approved | High | Not reported in the sources read | Injection | Prohibited in males, at all times (S2.2.1) |
| Trivehexin Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Trofinetide Full entry | Peptide | Cognitive | FDA Approved | High | ≈ 1.5 hours | Oral | Not on the 2026 List |
| Trofolastat Full entry | Small molecule, not a peptide | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Tuftsin Full entry | Peptide | Immune | Research Chemical | Medium | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Tyrothricin Full entry | Blend or mixture | Immune | Not FDA Approved | Medium | Not reported in the sources read | Topical or eye | Not on the 2026 List |
| Ubiquicidin 29-41 Full entry | Peptide | Research | In Clinical Trials | Medium | Blood mean residence time 0.52 hours in 6 children; about 85% of the activity left in the urine within 24 hours | Injection | Prohibited (S0 catch-all) |
| UBT251 | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Supports once-weekly dosing | Injection | Prohibited (S0 catch-all) |
| Ularitide Full entry | Peptide | Cardiovascular | Discontinued | High | ≈ 5.6 minutes | Injection | Prohibited (S0 catch-all) |
| Ulimorelin Full entry | Peptidomimetic | Metabolic | In Clinical Trials | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| Urocortin Full entry | Peptide | Cardiovascular | Research Chemical | Medium | ≈ 52 minutes | Injection | Prohibited (S0 catch-all) |
| Urocortin 2 Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Urocortin 3 Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans; an endogenous locally acting neuropeptide | Not stated | Not on the 2026 List |
| Urofollitropin Full entry | Protein, not a peptide | Sexual Health | FDA Approved | High | Not reported in the sources read | Not stated | Not on the 2026 List |
| Uroguanylin Full entry | Peptide | Metabolic | Research Chemical | Medium | Not stated in the sources read | Not stated | Prohibited (S0 catch-all) |
| Urotensin II Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not characterised in people | Injection | Prohibited (S0 catch-all) |
| Urotensin II-related peptide Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not stated in the sources read | Not stated | Not on the 2026 List |
| Utreglutide | Peptide | Pipeline & In-Development | In Clinical Trials | Low | Not published | Injection | Prohibited (S0 catch-all) |
| Vancomycin Full entry | Peptide | Immune | FDA Approved | High | ≈ 5 hours | Injection, Oral | Not on the 2026 List |
| Vapreotide Full entry | Peptide | Metabolic | In Clinical Trials | High | Not stated | Not stated | Prohibited (S0 catch-all) |
| Vasopressin Full entry | Peptide | Cardiovascular | FDA Approved | High | ≈ 10 minutes | Injection | Unsettled (S5 may apply) |
| Vasostatin (Chromogranin A) Full entry | Peptide | Cardiovascular | Research Chemical | Low | Not established for humans as a drug; an endogenous signalling peptide | Not stated | Not on the 2026 List |
| Veldoreotide | Peptide | Pipeline & In-Development | Not FDA Approved | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Ventfort | Peptide | Longevity | Not FDA Approved | Low | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| Vessel dilator Full entry | Peptide | Cardiovascular | Research Chemical | Medium | ≈ 107 minutes | Injection | Prohibited (S0 catch-all) |
| Vesugen | Peptide | Longevity | Research Chemical | Low | Not measured in the sources read | Not stated | Prohibited (S0 catch-all) |
| Vilon Full entry | Peptide | Longevity | Research Chemical | Low | Not stated | Not stated | Prohibited (S0 catch-all) |
| VIP Full entry | Peptide | Immune | In Clinical Trials | Medium | Minutes (cleared rapidly from plasma) | Injection | Unsettled (S0 may apply) |
| Vipivotide Tetraxetan Full entry | Peptidomimetic | Research | FDA Approved | High | ≈ 41.6 hours | Injection | Not on the 2026 List |
| Virginiamycin Full entry | Not a peptide | Immune | Veterinary Only | Low | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| Visoluten | Peptide | Longevity | Not FDA Approved | Low | Not reported in the sources read | Oral | Prohibited (S0 catch-all) |
| VK2735 | Peptide | Pipeline & In-Development | In Clinical Trials | Medium | Long-acting; given once weekly by injection | Injection | Prohibited (S0 catch-all) |
| VMT-α-NET Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | Not reported in the sources read | Injection | Prohibited (S0 catch-all) |
| Voclosporin Full entry | Peptide | Immune | FDA Approved | High | ≈ 30 hours | Oral | Not on the 2026 List |
| Vosoritide Full entry | Peptide | Growth Hormone | FDA Approved | High | ≈ 25 minutes | Injection | Not on the 2026 List |
| WE-14 Full entry | Peptide | Metabolic | Research Chemical | Low | Not established for humans as a drug; an endogenous granin peptide | Not stated | Not on the 2026 List |
| Xenin Full entry | Peptide | Metabolic | Research Chemical | Medium | Not stated in the sources read | Injection | Prohibited (S0 catch-all) |
| Zadavotide Guraxetan Full entry | Peptidomimetic | Research | In Clinical Trials | Medium | ≈ 35 hours | Injection | Prohibited (S0 catch-all) |
| Zelenectide Pevedotin Full entry | Peptide conjugate | Research | In Clinical Trials | Medium | 1-2 hours in rats and monkeys; no human figure in the abstracts read | Injection | Prohibited (S0 catch-all) |
| Zelpultide alfa | Protein, not a peptide | Pipeline & In-Development | In Clinical Trials | Low | Not reported in the sources read | Not stated | Prohibited (S0 catch-all) |
| Ziconotide Full entry | Peptide | Cognitive | FDA Approved | High | ≈ 4.6 hours | Not stated | Not on the 2026 List |
| Zilucoplan Full entry | Peptide | Immune | FDA Approved | High | ≈ 172 hours | Injection | Not on the 2026 List |
| Zoptarelin Doxorubicin Full entry | Peptide conjugate | Research | Discontinued | Medium | Not stated | Not stated | Prohibited (S0 catch-all) |
| αCT1 (Alpha Connexin Carboxyl-Terminus 1) Full entry | Peptide | Healing & Recovery | In Clinical Trials | Medium | Short; rapid metabolism of the free peptide is reported, motivating sustained-release and gel formulations | Topical or eye | Not on the 2026 List |
No entry matches these filters. Reset them or widen one.
How to read the columns
- Class says whether an entry is a peptide at all. Proteins, antibodies, small molecules and blends are marked as not peptides, from each entry's own description.
- FDA status is the US position only. "Not FDA Approved" can still mean approved elsewhere; the entry says where.
- Evidence is our grade of the human evidence: high for controlled human trials large enough to answer the question, typically a completed phase 3 programme or a reviewed approval dossier; medium for published human results short of that; low for cell or animal work, case reports, or nothing.
- Half-life shows a measured or labelled value when the entry has one; hover or tap for the source note. "Not measured" is a finding, not a gap in the table.
- Route is how the entry's studies or label give it, not a suggestion. An entry can have more than one.
- WADA 2026 is the sport status in the List in force. "Prohibited (S0 catch-all)" means, on our reading, an unapproved substance caught by WADA's catch-all section without being named; a substance the List names, such as BPC-157 under S0, shows as prohibited.
The dataset behind this table is updated as entries are rewritten; each entry page carries its last-reviewed date.